Chronic obstructive pulmonary disease: Role of bacteria and updated guide to antibacterial selection in the older patient

Drugs and Aging

Volumn 26, Issue 12, 2009, Pages 985-995

  Parameswaran, G Iyer ^a,b   Murphy, Timothy F ^a,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b GATES VASCULAR INSTITUTE AT KALEIDA HEALTH   (United States)

^c VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFPODOXIME; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; DOXYCYCLINE; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G; PENICILLINASE; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; SULFAMETHOXAZOLE; TAZOBACTAM; TRIMETHOPRIM;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE COURSE; DISEASE EXACERBATION; DYSPNEA; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMAN; INFECTION RISK; MORAXELLA CATARRHALIS; MORBIDITY; MORTALITY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RESPIRATORY FAILURE; REVIEW; SPUTUM; STRATIFICATION; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

AGED; AGING; ANTI-BACTERIAL AGENTS; HAEMOPHILUS INFECTIONS; HUMANS; MORAXELLACEAE INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 70849118894     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11315700-000000000-00000     Document Type: Review

References (49)

1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 2004 Jun; 23 (6): 932-946
2. Brown DW, Croft JB, Greenlund KJ, et al. Deaths from chronic obstructive pulmonary disease: United States, 2000-2005.MMWRMorb Mortal Wkly Rep 2008 Nov 14; 57 (45): 1229-1232
3. Liu S, Zhou Y, Wang X, et al. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. Thorax 2007 Oct; 62 (10): 889-897
4. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000 Feb; 117 (2 Suppl.): 5S-9S
5. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008 Nov 27; 359 (22): 2355-2365
6. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance: United States, 1971-2000. MMWR Surveill Summ 2002 Aug 2; 51 (6): 1-16
7. Isoaho R, Puolijoki H, Huhti E, et al. Prevalence of chronic obstructive pulmonary disease in elderly Finns. Respir Med 1994 Sep; 88 (8): 571-580
8. Yohannes AM, Roomi J, Waters K, et al. Quality of life in elderly patients with COPD: Measurement and predictive factors. Respir Med 1998 Oct; 92 (10): 1231-1236
9. Peruzza S, Sergi G, Vianello A, et al. Chronic obstructive pulmonary disease (COPD) in elderly subjects: Impact on functional status and quality of life. Respir Med 2003 Jun; 97 (6): 612-617
10. Cydulka RK, McFadden Jr ER, Emerman CL, et al. Patterns of hospitalization in elderly patients with asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997 Dec; 156 (6): 1807-1812
11. Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995 Dec 20; 274 (23): 1852-1857
12. Ranieri P, Bianchetti A, Margiotta A, et al. Predictors of 6-month mortality in elderly patients with mild chronic obstructive pulmonary disease discharged from a medical ward after acute nonacidotic exacerbation. J Am Geriatr Soc 2008 May; 56 (5): 909-913
13. Almagro P, Calbo E, Ochoa de Echaguen A, et al. Mortality after hospitalization for COPD. Chest 2002 May 2002; 121 (5): 1441-1448
14. Bonomo RA. Multiple antibiotic-resistant bacteria in long-term care facilities: An emerging problem in the practice of infectious diseases. Clin Infect Dis 2000; 31 (6): 1414-1422
15. Muder RR, Brennen C, Drenning SD, et al. Multiply antibiotic-resistant Gram-negative bacilli in a long-termcare facility: A case-control study of patient risk factors and prior antibiotic use. Infect Control Hosp Epidemiol 1997 Dec; 18 (12): 809-813
16. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006 May 15; 173 (10): 1114-1121 (Pubitemid 43726892)
17. Greenberg SB, Allen M, Wilson J, et al. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000 Jul; 162 (1): 167-173
18. Seemungal TA, Wedzicha JA. Viral infections in obstructive airway diseases. Curr Opin Pulm Med 2003 Mar; 9 (2): 111-116
19. Fagon JY, Chastre J, Trouillet JL, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis: Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 1990 Nov; 142 (5): 1004-1008
20. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease: A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995 Oct; 152 (4 Pt 1): 1316-1320
21. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998 May; 157 (5 Pt 1): 1498-1505
22. Rosell A, Monso E, Soler N, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005 Apr 25; 165 (8): 891-897
23. Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002 Aug 15; 347 (7): 465-471 (Pubitemid 34879333)
24. Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000 Sep; 109 (4): 288-295
25. Stockley RA, O'Brien C, Pye A, et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000 Jun; 117 (6): 1638-1645
26. White AJ, Gompertz S, Bayley DL, et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003 Aug; 58 (8): 680-685
27. Yi K, Sethi S, Murphy TF. Human immune response to nontypeable Haemophilus influenzae in chronic bronchitis. J Infect Dis 1997 Nov; 176 (5): 1247-1252
28. Bakri F, Brauer AL, Sethi S, et al. Systemic and mucosal antibody response to Moraxella catarrhalis after exacerbations of chronic obstructive pulmonary disease. J Infect Dis 2002 Mar 1; 185 (5): 632-640
29. Sethi S,Wrona C, Eschberger K, et al. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008 Mar 1; 177 (5): 491-497
30. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987 Feb; 106 (2): 196-204
31. Sachs AP, Koeter GH, Groenier KH, et al. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995 Jul 1; 50 (7): 758-763
32. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; (2): CD004403
33. Quon BS, Gan WQ, SinDD. Contemporary management of acute exacerbations of COPD: A systematic review and metaanalysis. Chest 2008 Mar; 133 (3): 756-766
34. Roede BM, Bresser P, Prins JM, et al. Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD. Eur Respir J 2009 Feb; 33 (2): 282-288
35. DimopoulosG, Siempos II, Korbila IP, et al. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: A metaanalysis of randomized controlled trials. Chest 2007 Aug; 132 (2): 447-455
36. Soler N, Agusti C, Angrill J, et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007 Jan; 62 (1): 29-35 (Pubitemid 46101763)
37. Johnson DM, Sader HS, Fritsche TR, et al. Susceptibility trends of Haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: Five-year report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003 Sep; 47 (1): 373-376
38. Sahm DF, Brown NP, Thornsberry C, et al. Antimicrobial susceptibility profiles among common respiratory tract pathogens: A GLOBAL perspective. Postgrad Med 2008 Sep; 120 (3 Suppl. 1): 16-24
39. Deshpande LM, Sader HS, Fritsche TR, et al. Contemporary prevalence of BRO b-lactamases in Moraxella catarrhalis: Report from the SENTRY Antimicrobial Surveillance Program (North America, 1997 to 2004). J Clin Microbiol 2006 Oct 1; 44 (10): 3775-3777
40. Musher DM. Streptococcus pneumoniae. In: Mandell GL, Douglas RG, Bennett JE, et al., editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th ed. Philadelphia (PA): Elsevier Churchill Livingstone, 2005: 2392-2411
41. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: A randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007 Jan; 131 (1): 9-19
42. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005 Dec 1; 26 (6): 1138-1180
43. Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis. Chest 1998 June 1998; 113 (6): 1542-1548
44. Blasi F, Tarsia P, Pappalettera M, et al. Antibiotic therapy and prophylaxis in COPD. Respir Med COPD Update 2007; 2 (4): 124-132
45. Falagas ME, Avgeri SG, Matthaiou DK, et al. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: A meta-analysis. J Antimicrob Chemother 2008 Sep; 62 (3): 442-450
46. Fletcher CM. Chronic bronchitis: Its prevalence, nature, and pathogenesis. Am Rev Respir Dis 1959 Oct; 80: 483-494
47. Banerjee D, Khair OA, Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J 2004 May; 23 (5): 685-691
48. Black P, Staykova T, Chacko E, et al. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst Rev 2003; (1): CD004105
49. Seemungal TAR, Wilkinson TMA, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008 Dec 1; 178 (11): 1139-1147